| Objective To retrospectively analyze plasma fibrinogen（FBG）, D-dimer（DD）, fibrin-degradation products（FDP） and platelet count（PLT） in patients with rheumatoid arthritis（RA） and to explore their relationships with inflammatory markers and disease activity. Methods The clinical data of RA in-patients admitted to the Department of Rheumatology and Immunology, Xuzhou Central Hospital, from January 2017 to December 2021 were collected. According to the DAS28-ESR score, patients were divided into the remission（n= 81）, moderate activity（n= 317） and high-activity groups（n= 323）. Coagulation indices were compared with erythrocyte sedimentation rate（ESR）, Creactive protein（CRP） and DAS28. Results DD, FDP, FBG and PLT in the high-activity group were higher than those in the moderateactivity group（P< 0.05）, and the moderate-activity group had higher levels than the remission group（P< 0.05）. Patients with elevated DD showed higher DAS28, ESR, CRP, rheumatoid factor（RF）, FDP, FBG and PLT than those with normal DD（P< 0.001）. After one year of tofacitinib therapy, triglyceride change was not significant, whereas DD decreased and total cholesterol increased（P< 0.05）. Plasma DD was positively correlated with ESR, CRP and DAS28（rs= 0.630, 0.635 and 0.393, respectively; P< 0.05）. FDP was positively correlated with ESR, CRP and DAS28（rs= 0.648, 0.658 and 0.414; P< 0.05）. FBG was positively correlated with ESR, CRP and DAS28（rs= 0.753, 0.753 and 0.410; P< 0.05）. PLT was positively correlated with ESR, CRP and DAS28（r= 0.499, 0.417 and 0.298; P< 0.05）. Conclusion The activation of the coagulation system in patients with rheumatoid arthritis is closely associated with disease inflammatory activity and severity. Monitoring plasma levels of FBG, DD, FDP, and PLT can provide additional evidence-based information beyond conventional inflammatory markers, contributing to a comprehensive assessment of disease status and prognosis in RA patients. This offers a solid foundation for the clinical use of routine coagulation parameters to assist in evaluating RA disease activity. |
